Virios Therapeutics (VIRI) News Today $2.60 +0.75 (+40.54%) (As of 11/19/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Dogwood says low-dose IMC-2 treatment reduces long-COVID fatigueNovember 18 at 6:35 PM | markets.businessinsider.comDogwood Study Finds IMC-2 Treatment Reduces Long-COVID Related Fatigue, Sleep DisturbanceNovember 18 at 6:35 PM | markets.businessinsider.comInovio Pharmaceuticals (NASDAQ:INO) Stock Quotes, Forecast and News SummaryNovember 16, 2024 | benzinga.comDogwood Therapeutics Announces Third Quarter Financial ResultsOn November 7, 2024, Dogwood Therapeutics, Inc. (Nasdaq: DWTX) disclosed its financial performance for the third quarter ending September 30, 2024. The company, newly formed in October thrNovember 13, 2024 | americanbankingnews.comDWTX: Phase 2 Long COVID Results Expected SoonNovember 12, 2024 | msn.comBuy Rating for Dogwood Therapeutics: Strategic Initiatives and Promising Pipeline Drive Analyst ConfidenceNovember 10, 2024 | markets.businessinsider.comDogwood Therapeutics Reports Q3 2024 Financial ResultsNovember 9, 2024 | markets.businessinsider.comDogwood Therapeutics Announces Third Quarter 2024 Financial ResultsNovember 8, 2024 | markets.businessinsider.comDogwood Therapeutics, Inc.: Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementOctober 31, 2024 | finanznachrichten.deDogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementOctober 30, 2024 | finance.yahoo.comVirios Therapeutics Transforms into Dogwood TherapeuticsOctober 8, 2024 | finance.yahoo.comMaintaining Hold on Virios Therapeutics Amid Merger and Clinical Development UncertaintiesOctober 8, 2024 | markets.businessinsider.comVirios, Wex Pharmaceuticals To Combine - Quick FactsOctober 7, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Virios Therapeutics, Inc. MergerOctober 7, 2024 | markets.businessinsider.comVirios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)October 7, 2024 | globenewswire.comVirios Therapeutics (NASDAQ:VIRI) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comAnalysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK), 60 Degrees Pharmaceuticals, Inc. (SXTP) and Gritstone Oncology (GRTS)August 15, 2024 | markets.businessinsider.comVIRI: Enrollment Complete in Phase 2a Long COVID Trial; Results Expected in October 2024…August 13, 2024 | msn.comBuy Rating for Virios Therapeutics Amid Promising Long COVID Treatment and Legislative TailwindsAugust 10, 2024 | markets.businessinsider.comHold Rating Maintained for Virios Therapeutics Amidst Financial Uncertainty and Pipeline ProspectsAugust 9, 2024 | markets.businessinsider.comVIRI Stock Earnings: Virios Therapeutics Beats EPS for Q2 2024August 8, 2024 | investorplace.comVirios Therapeutics Announces Second Quarter 2024 Financial ResultsAugust 8, 2024 | markets.businessinsider.comVirios Therapeutics Announces Second Quarter 2024 Financial ResultsAugust 8, 2024 | globenewswire.comVirios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024August 1, 2024 | globenewswire.comOptimistic Buy Rating for Virios Therapeutics as IMC-2 Advances in Clinical Trials with Promising Phase 2 ResultsJuly 25, 2024 | markets.businessinsider.comVirios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne CenterJuly 23, 2024 | globenewswire.comVirios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyMay 22, 2024 | globenewswire.comWhy Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day SessionMay 20, 2024 | msn.comWhy Is Virios Therapeutics (VIRI) Stock Down 44% Today?May 20, 2024 | investorplace.comVirios Therapeutics shares slid on pricing public offering of units to raise $1.7MMay 20, 2024 | msn.comVirios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyMay 19, 2024 | globenewswire.comVirios Therapeutics Plans To Sell Up To $2.1 Mln In Shares Of Its Common Stock In Public OfferingMay 18, 2024 | markets.businessinsider.comVirios Therapeutics Shares Tumble 35% on Stock OfferingMay 17, 2024 | marketwatch.comVirios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyMay 17, 2024 | globenewswire.comMaintaining Hold on Virios Therapeutics Amid Financial Strains and Clinical Development RisksMay 13, 2024 | markets.businessinsider.comVIRI: Results for Phase 2 Long COVID Trial Expected in 2H24…May 13, 2024 | finance.yahoo.comVirios Therapeutics, Inc. (NASDAQ:VIRI) Q1 2024 Earnings Call TranscriptMay 13, 2024 | finance.yahoo.comEarnings call: Virios Therapeutics reports on Q1 2024 progressMay 12, 2024 | uk.investing.comVirios Reveals Figures, Corporate UpdateMay 11, 2024 | msn.comVIRI Stock Earnings: Virios Therapeutics Misses EPS for Q1 2024May 9, 2024 | msn.comVirios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 9, 2024 | finanznachrichten.deVirios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 9, 2024 | globenewswire.comVirios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024May 2, 2024 | globenewswire.comVirios Therapeutics, Inc. (VIRI)April 14, 2024 | finance.yahoo.comVirios Therapeutics seeks global patent for antiviral comboMarch 28, 2024 | investing.comVirios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVIDMarch 26, 2024 | globenewswire.comVirios Therapeutics announces salary cuts for employees and boardFebruary 29, 2024 | investing.comVirios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial ResultsFebruary 29, 2024 | markets.businessinsider.comVirios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial ResultsFebruary 29, 2024 | globenewswire.comVirios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming MilestonesFebruary 28, 2024 | markets.businessinsider.com Get Virios Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRI and its competitors with MarketBeat's FREE daily newsletter. Email Address Top "Sleeping Giant" Crypto In The Market Now (Ad)Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future. Click here to discover our #1 crypto pick before it's too late VIRI Media Mentions By Week VIRI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VIRI News Sentiment▼-0.120.45▲Average Medical News Sentiment VIRI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VIRI Articles This Week▼31▲VIRI Articles Average Week Get Virios Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Neurogene News Editas Medicine News Corbus Pharmaceuticals News Opthea News Enanta Pharmaceuticals News Nanobiotix News ADC Therapeutics News Zura Bio News Compass Therapeutics News Heron Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VIRI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virios Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virios Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
